



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066
Email: info@smspharma.com, www.smspharma.com

Date 18th March, 2025

To,
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code:532815

Symbol: SMSPHARMA

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”), we would like to inform you that BSE Limited (BSE) and National Stock Exchange of India Ltd (NSE), have imposed fines on the Company via their emails dated 17th March, 2025 for the Non-Compliance of Regulation 19(1)(c) of SEBI (LODR) Regulations, 2015 pertaining to composition of Nomination and Remuneration Committee of the Company which stipulates that *‘at least two-thirds of the Directors shall be Independent Directors.’*

Whereas the Company while re-constituting the Nomination and Remuneration Committee it was initially proposed to comprise of three members, including two Independent Directors and one Non-Executive Director. However, during the Meeting finally, another Non-Executive Director was inadvertently inducted resulting in the Committee being constituted with four members w.e.f 12th August, 2024. It is pertinent to note that no Nomination and Remuneration Committee meetings were held, and no decisions were taken during this period. Hence, there was no material impact on the Company.

Upon subsequent review, the oversight was identified, and the Committee was reconstituted to align with the requirements of Regulation 19(1)(c) by removing one Non-Executive Director from the Committee with effect from 8th November 2024. Consequently, the Company complied with Regulation 19(1)(c) of SEBI (LODR) Regulations, 2015.

The details as required under SEBI Listing Regulations read with Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024 are provided below:

Name of the authority;	BSE Limited & National Stock Exchange of India Ltd.
Nature and details of the action(s) taken, initiated or order(s) passed	Fine of Rs. 2,000/- per day from 01 st October, 2024 to 07 th November, 2024 imposed by BSE



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,

Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

	Limited & National Stock Exchange of India Ltd, for non-compliance.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	17 th March, 2025
Details of the violation(s)/contravention(s) committed or alleged to be committed	Non-compliance of Regulation 19(1)(c) of SEBI LODR, with the requirements ' <i>at least two-thirds of the Directors shall be Independent Directors</i> ' pertaining to the composition of Nomination and Remuneration Committee of the Board for the period from 01 st October, 2024 to 07 th November, 2024.
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact of such fines on the financial, operation or other activities of the Company.

It is respectfully submitted that the non-compliance with SEBI (LODR) Regulations was unintentional, and the Company did not deliberately or wilfully avoid fulfilling any obligations under the said regulations. The Company remains committed to ensuring full compliance with all applicable laws.

The Stock Exchanges have already imposed a fine of Rs. 2,000/- per day from 12th August 2024 to 30th September 2024, which was communicated to the exchanges on 22nd November, 2024. The Company has duly paid the fine and submitted an application for a waiver, which is currently under process.

Further, in their latest email dated 17th March 2025, the Stock Exchanges have levied an additional fine for the period remaining period from 1st October 2024 to 7th November 2024. The Company will also consider filing an application for the waiver of this additional fine imposed by the Stock Exchanges.

We request you to kindly take the above on record.

Thanking you

For SMS Pharmaceuticals Limited

**Thirumalesh Tumma
Company Secretary & Compliance Officer**